Suggested remit: To appraise the clinical and cost effectiveness of ustekinumab within its marketing authorisation for treating moderately to severely active ulcerative colitis.
Status In progress
Process STA 2018
ID number 1511

Provisional Schedule

Expected publication 13 May 2020

Project Team

Project lead Thomas Feist

Email enquiries


Companies sponsors Janssen
Others Department of Health and Social Care
  NHS England
Patient carer groups Crohn's and Colitis UK
Professional groups British Society of Gastroentrology
  Royal College of Physicians
  United Kingdom of Clinical Pharmacy


Comparator companies Amgen
General commentators British National Formulary
  Department of Health and Social Services and Public Safety,
  Healthcare Improvement ScotlandNorthern Ireland (DHSSPSNI)
  Welsh Health Specialised Services Committee
  Scottish Medicines Consortium


Key events during the development of the guidance:

Date Update
25 February 2020 Committee meeting: 2
21 January 2020 - 11 February 2020 Appraisal consultation
10 December 2019 Committee meeting: 1
10 April 2019 In progress, In progress
10 April 2019 Invitation to participate
20 November 2018 - 18 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance